Tag: pathways

GILBERT, Ariz., July 14, 2025 (GLOBE NEWSWIRE) -- The Dr. Zachary Lipman Scholarship for Student Athletes is now open to applications from undergraduate students across the United States who are engaged in athletics and are determined to build careers within the sports industry. This initiative, created by Dr. Zachary Lipman, a leading physician in pain management and anesthesiology, offers meaningful academic support to individuals who blend athletic dedication with long-term professional goals in areas such as coaching, athletic training, sports management, and sports medicine.

PhenQ 2025 OTC Fat Burner for Men: Medically accredited supplement gains national traction with expert-backed multi-action formula and user trust.

Kuick Research Report highlights ongoing Clinical Development Technology platforms In Recent Research Study On KIF18A Therapies

Award Recognition underscores the importance of AI-driven drug discovery

HOUSTON, July 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the Advanced Wound Care Summit USA in Boston, Massachusetts, on July 15, 2025. The presentation will include recent research advances using fibroblast-based technology for indications such as wound healing and psoriasis.

SANTA ANA, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the administration of the first dose of troculeucel, an expanded autologous NK cell therapy, under a single compassionate use, Investigational New Drug (“IND”) authorization cleared by the U.S. Food and Drug Administration (“FDA”), to a patient with mild-stage Alzheimer’s disease who exhibited continued cognitive decline despite ongoing treatment with lecanemab, an amyloid targeting therapy. This exploratory work is being conducted in collaboration with Anita Fletcher, M.D., a board-certified neurologist with specialized training in neuroimmunology, who also serves as Director of Neuroscience Clinical Research at AdventHealth Neuroscience Institute in Orlando, Florida.